79Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Mexico
Neuroscience Intelligence
Mexico neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #31 of 50 · Data maturity A · Research score 33.7 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:34 UTC.
21Recruiting trials
32Publications
31Institutions
Executive interpretation
Mexico ranks #31 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Hoffmann-La Roche72 recruiting
Pfizer60 recruiting
Merck Sharp & Dohme LLC64 recruiting
Eli Lilly and Company50 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
UCB Pharma30 recruiting
Washington University School of Medicine33 recruiting
Bayer22 recruiting
Novartis Pharmaceuticals20 recruiting
GlaxoSmithKline20 recruiting
Disease activity
Alzheimers13trials
Epilepsy12trials
Parkinsons8trials
Depression5trials
Schizophrenia5trials
Other Neurology3trials
Adhd2trials
Anxiety2trials
Autism2trials
Migraine Headache2trials
Research institutions
Centro de Investigaciones en OpticaOpenAlexlinked institution
Centro Médico ABCOpenAlexlinked institution
Hospital Médica SurOpenAlexlinked institution
Instituto Nacional de PerinatologíaOpenAlexlinked institution
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico NacionalOpenAlexlinked institution
Universidad de la Sierra SurOpenAlexlinked institution
Universidad de GuadalajaraOpenAlexlinked institution
Secretaria de SaludOpenAlexlinked institution
Instituto Nacional de PediatriaOpenAlexlinked institution
National Institute of Genomic MedicineOpenAlexlinked institution
Clinical evidence trail
NCT07492069Life Skills-Based Intervention on Substance Use Intention in Adolescents in Social Care InstitutionsNOT_YET_RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT07174310A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's DiseaseRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantRECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRECRUITING
Research evidence trail
PUBMEDAssessing progesterone receptor modulation in glioblastoma: from in vitro and animal model to a human pilot protocol.2026-12-31
PUBMEDLong-term outcomes of microvascular decompression vs neurotomy for glossopharyngeal neuralgia: a multicenter clinimetric study.2026-12-01
PUBMEDClinical correlates of childhood- and adolescent-onset depression in a Mexican pediatric psychiatric cohort.2026-12-01
PUBMEDSleep stage-dependent distribution of interictal epileptiform discharges in epilepsy: A systematic review.2026-11-01
PUBMEDVortioxetine transiently alters basal locomotor activity but does not produce sedation in rats.2026-10-15
PUBMEDIsolation of adipose-derived mesenchymal stromal cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma.2026-10-01
PUBMEDEpidemiology and neurological profiling of vertebral tumors in Mexico: a five-year review from a tertiary referral center.2026-10-01
PUBMEDNeuropsychiatric disorders and gut dysbiosis: what is the real impact of the kynurenine pathway?2026-10-01
PUBMEDSelenium reverses zinc-induced differential dendritic remodeling in the dentate gyrus, CA1, and CA3 regions following transient ischemia in rats.2026-10-01
PUBMEDComparative efficacy and safety of rosuvastatin versus atorvastatin after acute ischemic stroke or transient ischemic attack: A systematic review and exploratory meta-analysis.2026-10-01
PUBMEDExperience, challenges, and regional integration of the National Dementia Biobank (Mexico) and the National Brain Bank-UNPHU (Dominican Republic).2026-10-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.